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Abstract 
Background: Heart failure (HF) is characterized by a series of adaptive changes in energy metabolism. The use of 
metabolomics enables the parallel assessment of a wide range of metabolites. In this study, we appraised whether 
metabolic changes correlate with HF severity, assessed as an impairment of functional contractility, and attempted to 
interpret the role of metabolic changes in determining systolic dysfunction.
Methods: A 500 MHz proton nuclear magnetic resonance (1H-NMR)-based analysis was performed on blood 
samples from three groups of individuals: 9 control subjects (Group A), 9 HF patients with mild to moderate impair-
ment of left ventricle ejection fraction (LVEF: 41.9 ± 4.0 %; Group B), and 15 HF patients with severe LVEF impairment 
(25.3 ± 10.3 %; Group C). In order to create a descriptive model of HF, a supervised orthogonal projection on latent 
structures discriminant analysis (OPLS-DA) was applied using speckle tracking-derived longitudinal strain rate as the 
Y-variable in the multivariate analysis.
Results: OPLS-DA identified three metabolic clusters related to the studied groups achieving good values for 
R2 [R2(X) = 0.64; R2(Y) = 0.59] and Q2 (0.39). The most important metabolites implicated in the clustering were 
2-hydroxybutyrate, glycine, methylmalonate, and myo-inositol.
Conclusions: The results demonstrate the suitability of metabolomics in combination with functional evaluation 
techniques in HF staging. This innovative tool should facilitate investigation of perturbed metabolic pathways in HF 
and their correlation with the impairment of myocardial function.
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Background
Heart failure (HF) is one of the most common chronic 
diseases in the USA and Europe [1]. Approximately 
1–2 % of the adult population in developed countries suf-
fers from HF [2] and, despite the availability of innovative 
therapies, it continues to be associated with an annual 
mortality rate of 10 %.
A growing body of evidence highlights the potential 
involvement of a decrease in cardiac energy metabolism 
in the pathogenesis and progression of HF [3]. During 
this metabolic remodeling, changes in substrate utiliza-
tion, oxidative phosphorylation, and high-energy phos-
phate metabolism occur. Cardiac energy metabolism 
can be fully evaluated in animal models or in myocardial 
specimens obtained by biopsy or from explanted hearts, 
but human evaluations in vivo are limited to the assess-
ment of glucose and fatty acid turnover rates [4], oxida-
tive phosphorylation [5], and ATP transfer by PET or 
NMR [6].
Metabolomics (MBS) is the study of the complete pro-
file of small-molecule metabolites in an organism and 
may provide a metabolic overview, not only resulting 
from changes in the expression of genes and RNA, but 
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also as a result of protein activity and environmental fac-
tors, including nutrition and drug therapies [7, 8]. MBS 
has been shown to have a substantial impact on the inves-
tigation of various cardiovascular diseases [7, 8] and the 
number of studies on its application for HF assessment 
is growing [9–11], however, sometimes with conflicting 
results [9, 10]. Recently, mass spectrometry-based profil-
ing of plasma metabolites was performed in over 400 HF 
patients by Cheng et al. in order to assess the diagnostic 
and prognostic value of MBS in HF. Their results showed 
that MBS is able to provide significant prognostic value, 
independent of brain natriuretic peptide (BNP) and other 
traditional risk factors [11].
In our study, a myocardial contractility parameter 
derived from echocardiography was used to build a 
metabolomic model of HF in which the metabolic vari-
ables are associated to systolic function, in order to bet-
ter identify metabolites linked to cardiac function rather 
than to the general metabolic status. Our aims were to 
verify the ability of this approach to discriminate HF 
patients from healthy subjects, and also to identify indi-
viduals with different degrees of myocardial dysfunction 
on the basis of their specific metabolic profiles.
Methods
Study design and population
The study was approved by the Institutional Ethics Com-
mittee (Azienda Ospedaliero-Universitaria, University of 
Cagliari) and was performed in accordance with the Dec-
laration of Helsinki. Enrolled subjects were informed of 
the purpose and methodology of the study and their writ-
ten consent was obtained prior to inclusion.
The study population included patients with HF 
(Table  1) who were consecutively admitted to our divi-
sion, and control subjects matched for sex, age, and body 
mass index, randomly selected from patients attending 
the departmental Outpatient Clinic (Table 1). The inclu-
sion criterion was presence of HF, diagnosed in accord-
ance with the European Society of Cardiology’s HF 
Guidelines [2]. Subjects with cachectic disease, non-con-
gestive hepatic or renal dysfunction, heritable metabolic 
disorders, or those who had previously undergone meta-
bolic therapy were excluded from the study. The exclu-
sion criterion for controls was the presence of more than 
one cardiovascular risk factor (overweight, high low-den-
sity lipoprotein and triglycerides, diabetes, hypertension, 
or habitual smoking).
The study population consisted of three groups: 9 
controls (Group A), 9 HF patients with mild-moderate 
impairment of left ventricle ejection fraction (LVEF 
35–50  %; Group B), and 15 HF patients with severe 
LVEF impairment (LVEF < 35 %; Group C). Patients and 
controls underwent a full cardiovascular assessment, 
including medical history evaluation, physical exami-
nation, blood pressure measurement, 12-lead electro-
cardiogram (ECG), and echocardiographic analysis. In 
addition, two blood samples were obtained by venipunc-
ture of the antecubital vein (4-mL Vacuette with EDTA 
and 10-mL Li-Heparin Vacuette, for BNP and MBS anal-
ysis, respectively).
BNP
Plasma concentrations of BNP were measured using a 
non-competitive immunofluorimetric test with high 
specificity (Triage® BNP Test, Biosite Inc., San Diego, 
CA, USA; normal values <100 pg/mL).
Conventional echocardiography and TDI and ST imaging
Echocardiographic assessments were conducted using a 
commercial system equipped with tissue Doppler imag-
ing (TDI) and speckle tracking (ST) echocardiography 
(Toshiba Artida-Toshiba Corp., Tochigi, Japan). At least 
three sets of loops, consisting of three consecutive car-
diac cycles, were stored for offline analysis. LVEF was 
measured using the modified Simpson’s biplane method 
from the apical 4- and 2-chamber view. Early filling (E 
wave) and atrial (A wave) peak velocities and E/A ratios 
were measured from transmitral flow. Using TDI, peak 
systolic (S), early diastolic (E′), and late diastolic (A′) 
mitral annular velocities were measured. Moreover, 
global longitudinal strain (GLS) and strain rate (SR) were 
evaluated using ST echocardiography.
MBS analysis
Heparinized blood samples were immediately centri-
fuged at 4000 rpm for 15 min. Then, the supernatant was 
divided into aliquots and stored at −80 °C.
Plasma chloroform/methanol/water extraction for NMR
All plasma samples were thawed and centrifuged at 
12,000  rpm for 10 min. The supernatants were processed 
using chloroform/methanol/water extraction. Specifically, 
800  μL of plasma was processed with 2.4  mL of chloro-
form/methanol (1:1, v/v) and 350 μL of H2O, vortexed for 
30  s, and centrifuged at 4500  rpm for 30  min. After cen-
trifugation, the hydrophilic and lypophilic fractions were 
collected. Approximately 1 mL of the hydrophilic fraction 
was dried overnight using a speed vacuum concentra-
tor (Eppendorf) and stored at −80 °C until NMR analysis. 
1H-NMR acquisition parameters and further data process-
ing details are reported in the Additional file 1: Supporting 
Information.
Multivariate statistical analysis
The multivariate statistical methods employed were: (1) 
the unsupervised principal components analysis (PCA) 
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for sample distribution overview, (2) projection to latent 
structures by partial least squares (PLS) regression, and 
(3) orthogonal partial least square discriminant analysis 
(OPLS-DA) for the identification of the most discrimi-
nant variables that characterize groups. PCA is a tech-
nique that transforms the variables in a dataset into a 
smaller number of new latent variables, known as prin-
cipal components. Each new principal component repre-
sents a linear combination of original variables, enabling 
the generation of a compact description of the variation 
within a given dataset. The OPLS-DA model maximizes 
the covariance between the measured data of the X-var-
iable (peak intensities in NMR spectra) and the response 
of the Y-variable (class assignment) within the groups. 
Useful parameters obtained from the OPLS-DA model 
were the variable influence on projection (VIP) scores 
and coefficients that describe the metabolite influence 
over all validated components. The model quality was 
evaluated on the corresponding partial least square dis-
criminant analysis (PLS-DA) model using a 7-fold cross-
validation and permutation test. The generated R2 and Q2 
values described the predictive ability and the reliability 
of the fitting, respectively.
Univariate statistical analysis
A one-way ANOVA (analysis of variance) with Fisher’s 
LSD test was performed on the anthropometric, clinical, 
and echocardiographic parameters of the three groups. 
Furthermore, the same test was applied to the NMR data, 
in order to assess which spectral regions, and therefore 
which metabolites, were mainly involved in each of the 
various groups. A P value of p < 0.05 was considered sta-
tistically significant.
The receiver operating-characteristic (ROC) curve was 
analyzed with sensitivity versus 1 −  specificity, and the 
area under the curve (AUC) was calculated using the free 
software package ROCCET: ROC Curve Explorer and 
Tester. An AUC  >  0.8 indicates a test with a good dis-
crimination between controls and patients.
Results
No appreciable differences were observed in any of the 
anthropometric parameters between the three groups 
(Table 1). In agreement with the study design, patients in 
group B were modestly symptomatic or virtually asymp-
tomatic, showing a substantial hemodynamic balance. 
Patients in group C showed clinical signs of HF. Each 
group included one subject affected by type II diabetes 
mellitus. All patients in groups B and C received optimized 
Table 1 Anthropometric and  clinical data of  the study 
population
BMI body mass index, BSA body surface area, DCM dilated cardiomyopathy
* p < 0.02 vs Group B
Group A  
(N = 9)
Group B  
(N = 9)
Group C 
(N = 15)
Age (years) 64.9 ± 8.3 66.1 ± 7.9 66.7 ± 9.9
M/F 7/2 8/2 10/5
Height (m) 1.63 ± 0.06 1.67 ± 0.51 1.67 ± 0.45
Weight (kg) 67.2 ± 12.4 74.0 ± 10.6 72.9 ±9.6
BMI (kg/m2) 25.2 ± 3.2 26.4 ± 3.9 26.04 ± 2.7
BSA (m2) 1.74 ± 0.17 1.85 ± 0.20 1.84 ± 0.26
Diabetes 1 1 1
NYHA class
 I 9 8 0
 II 0 1 2
 III 0 0 13*
 IV 0 0 0
Aetiology
 Ischaemic – 4 7
 Valvular – 1 1
 DCM – 4 6
 Hypertensive – 0 1
 Other – 0 0
Drugs
 β-blockers 9 14
 ACE-inhibitors – 6 9
 ARBs – 3 6
 Diuretics – 7 15
 Aldosterone 
antagonists
– 3 5
 Ca-antagonists – 4 1
 Antiarrythmics – 1 2
 Acetylsalicylic 
acid
– 6 10
 Antiplatelet 
agents
– 0 1
 Anticoagulants – 1 2
 Statins – 7 9
 Other hypolipi-
demic 
agents
– 0 3
 Insulin – 1 1
 Oral antidia-
betic agents
– 1 1
 Digoxin – 1 1
 Nitroderivates – 2 0
 Other antihy-
pertensive 
drugs
– 1 0
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standard therapy, in line with their functional class and rel-
ative international recommendations [2]. Additionally, no 
significant differences were found between the two groups 
in terms of pharmacological treatment (Table 1).
BNP
BNP values were in the normal range in groups A and 
B, but they were significantly increased in group C 
(p < 0.001; Fig. 1). The fact that healthy subjects in group 
A cannot be distinguished from those of group B on the 
basis of BNP is also noteworthy.
Echocardiographic data
LVEF featured normal values in group A, a mild to mod-
erate impairment in group B vs. group A (p < 0.001), and 
a severe decrease in group C vs. group A and group B 
(p < 0.001). The progressive deterioration of LV function 
in the transition from group A to group B, and from the 
latter to group C, was confirmed by TDI and ST (Table 2; 
Fig. 2).
A statistically significant difference in E/E′ ratio was 
observed in group C vs. group A, while no difference 
was found between group B and either group A or C 
(Table  2). However, E/E′ revealed a trend of moderate 
diastolic dysfunction in group B.
Intraobserver variability was previously reported for 
our EchoLab [12].
1H‑NMR
The representative 1H-NMR spectra of plasma hydro-
philic extracts of each of the three groups of samples are 
shown in Fig. 3. The spectral peaks were assigned to indi-
vidual metabolites on the basis of literature research and 
using the 500  MHz library from Chenomx NMR suite 
7.1 (Chenomx Inc., Edmonton, Alberta, Canada). Major 
peak assignments of plasma samples are illustrated in 
Fig. 3 and chemical shifts of all metabolites are summa-
rized in Additional file 1: Table S1.
An unsupervised PCA was initially applied to the whole 
dataset to visualize possible metabolic differences among 
the groups, while at the same time identifying potential 
outliers. The first three PCs described 64.8 % of the vari-
ance, and all the samples were within the Hotelling’s T2 
confidence ellipse. The PC2 vs. PC3 score plot (Fig.  4a) 
shows a clear tendency of samples to cluster on the basis 
of systolic function. In particular, along PC2, group C is 
separated form groups A and B, while these two are sepa-
rated along PC3. These results clearly show that the three 
classes of samples have different metabolic profiles.
To investigate which metabolites significantly contrib-
ute to the observed separation, an OPLS-DA was applied 
to the spectral data. The score plot of the first and sec-
ond predictive latent variable is shown in Fig.  4b. As 
illustrated, a good separation was observed between the 
three groups of samples. OPLS-DA modeling produced 
a model with three components, with R2(X)  =  0.64, Fig. 1 BNP values in the three groups
Table 2 Echocardiographic data in the three groups
LVEF left ventricle ejection fraction, S systolic peak velocity, GLS global 
longitudinal strain, E early ventricular filling peak velocity, A atrial (late) peak 
velocity, E′ early mitral annular velocity, A′ late mitral annular velocity
* p < 0.05 vs Group A; # p < 0.01 vs Group A; ##p < 0.001 vs Group A; ∫p < 0.05 vs 
Group B; ∫∫p < 0.001 vs Group B
Group A Group B Group C
Systolic function
 LVEF (%) 61.3 ± 5.8 41.9 ± 4.0## 25.3 ± 10.3##,∫∫
 S (cm/s) 7.63 ± 3.0 5.42 ± 1.91# 4.62 ± 1.84##,∫
 GLS (%) 15.6 ± 3.2 9.9 ± 1.5## 4.9 ± 2.2##,∫∫
Diastolic function
 E/A 0.89 ± 0.30 0.74 ± 0.30 1.79 ± 1.70
E′/A′ 0.78 ± 0.30 0.78 ± 0.38 0.79 ± 0.45
E/E′ 9.83 ± 3.78 12.50 ± 5.95 21.07 ± 12.21*
Fig. 2 Longitudinal SR values in the three groups (one way ANOVA 
p < 0.0001)
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R2(Y)  =  0.59, and Q2(Y)  =  0.39, thereby indicating a 
good capacity for fitting and prediction. Additional 
information was obtained from the OPLS-DA model, 
through the study of the VIP scores and regression coef-
ficients. In particular, VIP analysis allowed the identifi-
cation of the metabolites contributing to the separation. 
The VIP value was used to reflect variable importance. 
Variables with a VIP score >1 were taken into considera-
tion and the corresponding coefficient values for each 
class were studied to attribute discriminant metabolites 
to a specific group. The positive or negative value of the 
coefficient was used to determine upward or downward 
variation of the metabolite in the investigated spectral 
regions. The most significantly characterizing metabo-
lites are reported in Table  3 and shown in Additional 
file 1: Fig. S1.
To understand the actual trend of the metabolites 
highlighted in Table 3, their relative concentrations were 
determined using Chenomx NMR and spectral regions 
were normalized and subjected to a one-way ANOVA 
test. Four metabolites (2-hydroxybutyrate, glycine, meth-
ylmalonate, and myo-inositol) showed significant varia-
tion. The performance of these metabolites was evaluated 
individually in the three groups with box-and-whisker 
plots (Fig.  5). Interestingly, group C exhibited a lower 
2-hydroxybutirate content, but a higher content of gly-
cine and myoinositol than groups A and B. Conversely, 
the methylmalonate content was higher in group B 
than in groups A and C. The combined performance of 
2-hydroxybutyrate, glycine, and myo-inositol was evalu-
ated using ROC curves. The levels of the three metabo-
lites allowed to distinguish patients with severe HF, both 
Fig. 3 Spectral area assignments of a representative 1H NMR spectra of plasma obtained from a group A, b group B, and c group C. Peaks 
2-hydroxybutyrate (2-HB), 3-hydroxybutyrate (3-HB), 3-methyl-2-oxovalerate (oxoVal), 4-aminobutyrate (4-AB), acetate (Ac), alanine (Ala), choline 
(Cho), citrate (Cit), creatine (Cr), creatinine (Crn), fucose (Fuc), glucose (Glc), glycine (gly), glycero-3-phosphocholine (G-PCho), glutamate (Glu), 
glutamine (Gln), guanidoacetate (GAc), isobutyrate (IsoB), isoleucine (Iso), lactate (Lac), leucine (Leu), methionine (Met), methylmalonate (MMal), 
methylhistidine (MHis), myo-inositol (myo-I), N-acetyl groups (A-groups), phenylacetylglycine (PAgly), phosphocholine (PCho), proline (Pro), trimeth-
ylamine N-oxide (OTMA), tryptophan (Trp), and tyrosine (Tyr)
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from those with mild to moderate disease and from 
healthy controls with an AUC  >  0.80 (Additional file  1: 
Fig. S2).
Finally, a PLS regression analysis was carried out in 
order to evaluate the relationship between different meta-
bolic profiles and longitudinal SR (Fig. 6). The good over-
all correlation resulting from PLS regression [R2 = 0.750, 
and the R2(Y) and Q2(Y) values of 0.746 and 0.58, respec-
tively] indicates the efficiency of the regression fitting and 
predictability of the resulting PLS mode. The permuta-
tion test, used to evaluate the statistical significance of 
the estimated predictive power of the model, shows an 
R2(Y) intercept of 0.293 and a Q2(Y) intercept of −0.222, 
thus confirming the validity of the PLS model.
Discussion
This study focused on the MBS investigation of two 
groups of HF patients with mild-to-moderate and severe 
impairment of systolic function. The two groups of 
patients were compared with a control group using lon-
gitudinal SR as a landmark continuous variable of systolic 
function in order to try to trace metabolic alterations 
Fig. 4 PCA scores (a) and OPLS-DA scores plots (b) of 1H NMR spectra of plasma samples: group A (circle), group B (box), and group C (triangle)
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linked to myocardial contractility. The results show that: 
(a) MBS can identify a metabolic fingerprint specific for 
each HF stage, independent of BNP levels, which were 
similar in controls and patients with mild-to-moderate 
HF, and (b) different metabolic profiles are related to 
contractile function, as determined by longitudinal SR.
Cardiac metabolic abnormalities in HF may reflect 
both an increase in energy demand, and an impaired 
ability to generate a sufficient amount of ATP. Given that 
the heart is highly dependent on ATP, impairment of this 
process can rapidly induce contractile dysfunction [13, 
14]. In order to recruit its residual contractile reserve, 
the failing heart consumes a disproportionate amount of 
energy, which is associated with worse clinical outcomes 
[15]. On this basis, longitudinal SR was used as an index 
of cardiac contractility and was correlated with metabolic 
Table 3 Metabolites identified to have a VIP score greater than 1 through the OPLS-DA model of the three sample classes 
and corresponding regression coefficient values
Higher value of the coefficients indicates higher comparative level of the corresponding metabolite in the class
Class Variables VIP Coefficient values Metabolites
Group A Group B Group C
Group A 1.94 2.46 0.14 −0.07 −0.06 Acetate
0.9 2.40 0.07 0.05 −0.11 2-Hydroxybutyrate
0.98 2.27 0.11 −0.02 −0.08 Leucine/isoleucine
0.94 1.92 0.08 −0.01 −0.07 Leucine/isoleucine
1.66 1.88 0.05 0.03 −0.08 2-Hydroxybutyrate/leucine
1.18 1.67 0.09 −0.04 −0.04 3-Hydroxybutirate/ fucose
1.46 1.52 0.06 −0.01 −0.05 Alanine/isoleucine
1.5 1.44 0.04 0.03 −0.06 Alanine/isoleucine
2.42 1.26 0.06 −0.06 0.01 3-Hydroxybutirate/glutamina
1.1 1.22 0.05 0.01 −0.05 3-Methyl-2-oxovalerate
1.7 1.20 0.04 −0.05 0.01 2-Hydroxybutyrate
1.22 1.18 0.04 −0.05 0.01 3-Hydroxybutirate/ fucose
Group B 3.38 3.45 −0.22 0.13 0.08 Proline/methanol
3.9 2.12 −0.08 0.07 0.01 Glucose
3.22 1.78 −0.05 0.11 −0.06 Glycero-3-phosphocholine
3.94 1.76 −0.06 0.07 −0.01 Glucose/creatine
1.9 1.71 −0.07 0.11 −0.04 4-Aminobutyrate
3.42 1.54 0.03 0.08 −0.10 Glucose
3.74 1.45 −0.01 0.01 0.00 Glucose
1.26 1.44 −0.04 0.09 −0.05 Methylmalonate
1.86 1.25 −0.01 0.06 −0.05 4-Aminobutyrate
2.34 1.17 −0.03 0.07 −0.04 3-Hydroxybutirate/glutamate
3.98 1.07 −0.08 0.04 0.04 2-Hydroxybutyrate
2.7 1.01 −0.07 0.05 0.02 Citrate
1.34 4.43 0.00 −0.23 0.22 Lactate
3.7 3.05 −0.15 0.01 0.12 Glucose
Group C 3.66 2.52 −0.12 −0.02 0.13 Glucose/glycero-3-phosphocholine
3.62 2.50 −0.11 −0.03 0.13 Myo-inositol/glycero-3-phosphocholine
3.58 2.40 −0.07 −0.05 0.11 Myo-inositol/glycine
3.82 1.94 −0.03 −0.06 0.08 Glucose/guanidoacetate
4.14 1.65 0.00 −0.09 0.08 Lactate
3.3 1.51 −0.03 −0.05 0.07 Myo-inositol/glycine/OTMA
4.02 1.48 −0.08 0.01 0.06 2-Hydroxybutyrate
2.06 1.36 −0.06 −0.04 0.10 N-acetyl groups
4.06 1.09 −0.05 −0.01 0.05 Myo-inositol/creatinine
3.14 1.02 −0.08 0.03 0.04 Methylmalonate
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changes that occur in HF. Several studies have shown 
that this parameter deteriorates precociously in cardiac 
disease, prior to the onset of clinical symptoms and LVEF 
reduction [16]. In addition, longitudinal SR is predictive 
of death or hospitalization for HF and adds an additional 
value in predicting death from any cause beyond LVEF 
Fig. 5 Box-and-whisker plots of the metabolite levels in patients with mild-moderate and severe HF (groups B and C groups) relative to healthy 
controls (group A). P values from one-way ANOVA with Fisher’s LSD test are displayed in the upper right corner of each plot
Fig. 6 Predicted vs. measured longitudinal SR from PLS regression with NMR metabolic profiles of the three groups [group A (circle), group B (box) 
and group C (triangle)] as X-variables and longitudinal SR as the Y-variable
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[17]. The use of this parameter as the Y-variable in a mul-
tivariate analysis enabled us to identify the fingerprints of 
two well-separated stages of HF, that are associated with 
compensated myocardial function and advanced cardiac 
failure, highlighting the different metabolic frameworks 
correlated with the corresponding clinical features, and 
with increasing functional and metabolic impairment.
The use of MBS in HF has been recently evaluated in 
several studies, sometimes with contrasting results. In 
2013, Tenori investigated the metabolomic fingerprint of 
the disease and its relationship with the levels of N-ter-
minal of the prohormone brain natriuretic peptide and 
New York Heart Association (NYHA) classes in patients 
with chronic HF. He concluded that MBS is able to iden-
tify a metabolic cluster of HF, which correlates with the 
presence of disease, irrespective of its severity [10]. On 
the other hand, a study similar to ours classified HF 
patients in three groups of progressive disease severity, 
each characterized by a specific metabolic fingerprint [9]. 
The authors used the level of myocardial energy expendi-
ture (MEE) as an index of cardiac performance. However, 
MEE is derived from the stroke volume and is based on 
the assessment of global LV performance. Parameters 
derived from regional and global LV function are not very 
sensitive, because they are highly dependent on loading 
and are likely to produce abnormal results if obtained 
under unusual load conditions, as is the case in HF [18]. 
More recently, Cheng et al. performed a mass spectrom-
etry-based profiling of plasma metabolites in over 400 
HF patients and 114 control subjects in order to evaluate 
the diagnostic and prognostic value of metabolomics in 
HF. The metabolic fingerprint resulting from this critical 
study consisted of histidine, phenylalanine, spermidine, 
and phosphatidylcholine C34:4, and has been shown to 
have a diagnostic value comparable to that of BNP. In 
addition, using the combined endpoints of death or HF-
related rehospitalization, a metabolic panel, including 
the asymmetric methylarginine/arginine ratio, butyryl-
carnitine, spermidine, and the total amount of essential 
amino acids, revealed a prognostic value independent of 
traditional risk factors, and more robust than that of BNP 
[11].
BNP is a widely used biomarker for the diagnosis and 
management of patients with recognized HF and an 
extensive body of evidence supports its use [2]. It is there-
fore important to emphasize that, while the OPLS-DA 
model based on different metabolic profiles in our study 
showed a significant cluster among the three groups, 
BNP levels were unable to differentiate patients with 
mild-to-moderate HF (group B) from control subjects 
(group A). The normal values of BNP that we found in 
patients with mild-to-moderate LV impairment probably 
reflect the balanced clinical condition of these patients. 
These findings seem to be consistent with the results of 
Cheng et al., as stated above [11].
The OPLS-DA model identified a set of metabolites 
that were decisive in determining the clustering of data 
originating from our subjects: glycine, myo-inositol, 
2-hydroxybutyrate, and methyl-malonate. Beyond the 
diagnostic and clinical implications, the identification 
of the metabolic parameters in this study can lead to 
a deeper understanding of the pathophysiology of HF. 
In this respect, the broad spectrum of metabolites and 
their particular combination in MTB fingerprints could 
promote a more accurate interpretation of the adaptive 
metabolic response of the failing heart.
In myocardial hypertrophy and chronic HF, there is a 
decline in total creatine (Cr), due to a mismatch between 
the need for ATP and its actual production. The loss of 
Cr is myocardial-specific and occurs approximately one 
order of magnitude faster than that of ATP. Cr is synthe-
sized primarily in the liver and pancreas from the amino 
acids glycine and arginine [19]. In accordance with this 
finding, we observed an increase in the levels of glycine 
in HF patients compared to controls, as well as a greater 
presence of this amino acid in group B than in group 
A. In patients with end-stage HF, there was an elevated 
myocardial activity of arginine-glycine aminotransferase, 
which decreases during recovery, due to therapy with 
left ventricular assist devices. This suggests that a spe-
cific metabolic response to HF involves high rates of local 
Cr synthesis [20]. In addition to its role in Cr synthesis, 
intracellular glycine has a protective effect against reoxy-
genation injury in mitochondria of cardiomyocytes sub-
jected to ischemia or Ca2+-stress under normoxia [21]. 
Moreover, a role of this metabolite has been suggested 
in preserving energy production in the mitochondria of 
cancer cells or myocytes during acute cellular stress [22].
Group C was also characterized by higher levels of 
myo-inositol, an essential component of the plasma 
membrane that acts as an intracellular second messenger 
[23]. A rapid turnover of myo-inositol and of its phos-
phate compounds was identified after adrenergic stimuli 
[24] and was associated with sarcoplasmic calcium over-
load and the development of cardiomyopathies in rats 
[25]. Although a recent report of Santulli showed that 
leaky ryanodine, but not inositol-trisphosphate (I3P), 
receptors/calcium channels are able to determine mito-
chondrial Ca2+ overload and dysfunction in HF [26], Go 
et  al. previously has demonstrated a decrease in ryano-
dine receptors mRNA by 31 % in the left ventricle of fail-
ing hearts, while IP3 receptors and the relative amount 
of IP3 binding sites were increased by, respectively 123 % 
and approx. 40 % [27]. Therefore, the observed increase 
in the levels of myo-inositol could be part of a compen-
satory response in advanced stages of HF. On the other 
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hand, the same IP3 receptors may play a role in cardio-
myocyte apoptosis and, therefore, in the progression of 
HF [28, 29].
The significance of changes in circulating and intracar-
diac ketone bodies in HF is still under investigation. Alex-
ander et al. found high serum levels of 2-hydroxybutyrate 
in dilated cardiomyopathy patients. On the contrary, 
we observed lower concentrations of this metabolite in 
group C than in the control group. Previous MBS stud-
ies showed that the extraction of cardiac ketone bodies 
from the plasma depends on their concentration in cir-
culation [30, 31], rather than on the presence and degree 
of LV dysfunction [29]. These results were confirmed by 
Psychogios, who reported higher levels of 2-hydroxybu-
tyrate in healthy subjects than in patients who underwent 
heart transplantation [32].
The last metabolite identified in the univariate analy-
sis, methylmalonate, was higher in patients from group B 
than in the other two groups. Kang and Chung, in 2011 
and in 2012, respectively, demonstrated the presence of 
high levels of methylmalonate in urine samples of HF 
patients. Methylmalonate is an intermediate of one of 
the anaplerotic pathways, thus helping to maintain the 
efficiency of the Krebs cycle. Changes in the Krebs cycle 
precede the deterioration of systolic function [33] and 
a correlation between efficiency of the citric acid cycle 
and systolic function was detected [34]. On the basis of 
our data, it is conceivable that in HF patients in hemo-
dynamic equilibrium, the increase of methylmalonate is 
caused by the activation of the anaplerotic pathway, in an 
attempt to maintain the necessary production of chemi-
cal energy through the Krebs cycle. This ability could 
have helped to maintain the functional capacity and 
hemodynamic compensation of these patients.
Taken together, the findings of our study describe 
a unique metabolic profile, discriminating not only 
between HF patients and controls, but also between 
HF subjects with mild-to-moderate and severe systolic 
dysfunction, suggesting that a progressive depletion 
of energy reserves could be the cause of the develop-
ment of cardiac impairment. Therefore, MBS associated 
with functional data, such as longitudinal SR, appears 
to accurately reflect the metabolic changes underly-
ing myocardial dysfunction in HF. Our data suggest a 
boosted energetic metabolism in early/compensated HF 
states, and a depletion of metabolic capacity that leads 
to a progressive systolic impairment in more severe HF 
cases.
Limitations of the study
The small number of samples included in this study rep-
resents a considerable limitation. However, the sensitivity 
of the technique, together with the complimentary 
approaches used (clinical, echocardiographic, and MBS) 
enabled us to construct a promising model.
Conclusions
MBS, in association with more traditional cardiac param-
eters, could be a valuable method for performing a thor-
ough examination of the pathophysiology of HF and the 
metabolic alterations that accompany its deterioration.
From a practical point of view, the characterization of 
a myocardial impairment that is still free of symptoms 
could enable a more careful monitoring of at-risk individ-
uals, allowing the anticipation of systolic function impair-
ment and/or the development of an episode of overt 
failure. Clinical applications could be various: (1) moni-
toring chronic HF patients, including those waiting for a 
heart transplant, as well as relatives of subjects affected 
by heritable cardiomyopathies, and (2) early detection of 
cardiac involvement during cardiotoxic treatments (e.g., 
anthracycline therapy).
In addition, recognition of the metabolic pathways 
involved in the progression of the disease may help to 
identify new therapeutic targets at the molecular level, 
which could in the future enable medical providers to 
stop or reverse the myocardial and systemic adaptations 
of cardiac insufficiency.
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